MiraLAX generic
This article was originally published in The Tan Sheet
Executive Summary
Perrigo expects to ship immediately its OTC laxative polyethylene glycol 3350, powder to solution, following FDA approval of an abbreviated new drug application. Positioned as an equivalent to Schering-Plough Healthcare Products' MiraLAX laxative, the OTC drug will be sold under store-brand labels, the company notes. Perrigo had said it would be market-ready when Schering's exclusivity for the laxative drug expired Oct. 6 (1"The Tan Sheet" July 13, 2009)
You may also be interested in...
Perrigo expects private-label MiraLAX launch in October
The firm prepares to be market-ready when Schering-Plough's exclusivity expires Oct. 6 for its OTC laxative MiraLAX. The expiry brings the "market formation date" and Perrigo expects "to be there," said Art Shannon, VP of investor relations and communications. Without exclusivity for the innovator, other firms can ask FDA to approve abbreviated new drug applications for equivalent products. Firms do not receive ANDA approval for the product until closer to Oct. 6, Shannon explained
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.